COMPANY

Nuvalent

HQ: Cambridge, MA source · nuvalent.com ↗ · New England

Status: Acquired, now part of GSK · How status works

New owner: Acquired by GSK (closed 2026-07-15) · source (Jul 15, 2026) · Ownership changes

FDA-approved therapeutic company Clinical Phase 3

3 open jobs · last seen Oct 23, 2026 · 7 sources

Keywords: oncology cancer Non-small Cell Lung Cancer Anaplastic Lymphoma Kinase-positive ALK-positive Non-small Cell Lung Cancer (NSCLC) ROS1-positive Non-Small Cell Lung Cancer (NSCLC) Neladalkib (NVL-655) Zidesamtinib (NVL-520) NVL-655 NVL-520 NVL-330

Profile checked Oct 10, 2026

Since the raise (Nov 20, 2025): 3 of 3 open jobs were first seen after it.

3Open jobs $500.0MRaised (2 yrs)6Trials (company is sponsor)1FDA records (2 yrs)

Hiring

Title	Location (from posting)	Employer posted	First seen
Director, JIDEYTRO HCP Marketing	Remote	Oct 15, 2026	Oct 16, 2026
Director, Medical Affairs Strategy	Remote	Aug 5, 2026	Oct 5, 2026
Director, National Thought Leader Liaison	Remote	Jun 2, 2026	Oct 5, 2026

See all 3 jobs

Trial and FDA signals

Drug approval + hiring FDA novel approval for JIDEYTRO (NDA 220185, Jul 22, 2026); since then posted 2 manufacturing/quality or commercial roles. FDA NDA 220185 (Jul 22, 2026)
Evidence (1 event)
- Jul 22, 2026 · FDA NDA 220185
  openFDA drugsfda: application_number=NDA220185; sponsor_name='NUVALENT'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260722; submission_class_code=TYPE 1; brand_name=['JIDEYTRO']

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

Oct 5, 2026 Board tracked Radar started tracking this company’s job board (3 open jobs at last check). source ↗
Jul 22, 2026 FDA FDA New drug/biologic (novel): JIDEYTRO (zidesamtinib) — NDA220185, Jul 22, 2026. Applicant at approval: Nuvalent, Inc. source ↗
Nov 20, 2025 Raise Follow-on offering: $500M (total, as published), announced Nov 20, 2025. Source: SEC filing. source ↗
Jul 17, 2025 Trial start Phase 3: Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC source ↗
Jul 18, 2024 Trial start Phase 1: A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) source ↗
Jun 9, 2022 Trial start Phase 1/Phase 2: A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) source ↗
Jan 4, 2022 Trial start Phase 1/Phase 2: A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) source ↗

Upcoming milestones

2027-01 (ESTIMATED) · Phase 1 · A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) · NCT06521554
2027-12 (ESTIMATED) · Phase 1/Phase 2 · A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) · NCT05384626
Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) · NCT05118789
2029-12 (ESTIMATED) · Phase 3 · Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC · NCT06765109

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 3

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Director, JIDEYTRO HCP Marketing	Remote	Oct 15, 2026	Oct 16, 2026	Not stated
Director, Medical Affairs Strategy	Remote	Aug 5, 2026	Oct 5, 2026	Senior
Director, National Thought Leader Liaison	Remote	Jun 2, 2026	Oct 5, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $500.0M. Last 2 years.

Nov 20, 2025 Follow-on offering: $500M (total, as published), announced Nov 20, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT06765109	Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC	Phase 3	Recruiting	Jul 17, 2025	2029-12 (estimated)
NCT05118789	A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)	Phase 1/Phase 2	Recruiting	Jan 4, 2022	Dec 31, 2027 (estimated)
NCT06834074	Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors	Not listed	Available	Not listed	Not listed
NCT06797362	Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors	Not listed	Available	Not listed	Not listed
NCT05384626	A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)	Phase 1/Phase 2	Recruiting	Jun 9, 2022	2027-12 (estimated)
NCT06521554	A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)	Phase 1	Recruiting	Jul 18, 2024	2027-01 (estimated)

FDA records (last 2 years)

Jul 22, 2026 FDA New drug/biologic (novel): JIDEYTRO (zidesamtinib) — NDA220185, Jul 22, 2026. Applicant at approval: Nuvalent, Inc. source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗

Connect

See your connections at Nuvalent on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12